Anavex 2-73 Seen to Safely Ease Rett Severity in Women in Phase 2 Trial
Anavex 2-73 (blarcamesine), an investigational treatment for Rett syndrome, lessened the disease’s characteristic behavioral features, its severity, and levels of the glutamate biomarker with no serious side effects, top-line results of a Phase 2 clinical trial in adult patients show. Based on these findings, Anavex Life…